226 related articles for article (PubMed ID: 37316586)
1. Correlating MRI features with additional genetic markers and patient survival in histological grade 2-3 IDH-mutant astrocytomas.
Lasocki A; Buckland ME; Molinaro T; Xie J; Whittle JR; Wei H; Gaillard F
Neuroradiology; 2023 Aug; 65(8):1215-1223. PubMed ID: 37316586
[TBL] [Abstract][Full Text] [Related]
2. Qualitative and Quantitative Magnetic Resonance Imaging Phenotypes May Predict CDKN2A/B Homozygous Deletion Status in Isocitrate Dehydrogenase-Mutant Astrocytomas: A Multicenter Study.
Park YW; Park KS; Park JE; Ahn SS; Park I; Kim HS; Chang JH; Lee SK; Kim SH
Korean J Radiol; 2023 Feb; 24(2):133-144. PubMed ID: 36725354
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of MTAP and p16 immunohistochemical deficiency as surrogate marker for CDKN2A/B homozygous deletion in gliomas.
Maragkou T; Reinhard S; Jungo P; Pasquier B; Neuenschwander M; Schucht P; Vassella E; Hewer E
Pathology; 2023 Jun; 55(4):466-477. PubMed ID: 37032198
[TBL] [Abstract][Full Text] [Related]
4. Homozygous deletion of CDKN2A by fluorescence in situ hybridization is prognostic in grade 4, but not grade 2 or 3, IDH-mutant astrocytomas.
Marker DF; Pearce TM
Acta Neuropathol Commun; 2020 Oct; 8(1):169. PubMed ID: 33081848
[TBL] [Abstract][Full Text] [Related]
5. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
Appay R; Dehais C; Maurage CA; Alentorn A; Carpentier C; Colin C; Ducray F; Escande F; Idbaih A; Kamoun A; Marie Y; Mokhtari K; Tabouret E; Trabelsi N; Uro-Coste E; Delattre JY; Figarella-Branger D;
Neuro Oncol; 2019 Dec; 21(12):1519-1528. PubMed ID: 31832685
[TBL] [Abstract][Full Text] [Related]
6. Conventional MRI features can predict the molecular subtype of adult grade 2-3 intracranial diffuse gliomas.
Lasocki A; Buckland ME; Drummond KJ; Wei H; Xie J; Christie M; Neal A; Gaillard F
Neuroradiology; 2022 Dec; 64(12):2295-2305. PubMed ID: 35606654
[TBL] [Abstract][Full Text] [Related]
7. Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytoma.
Satomi K; Ohno M; Matsushita Y; Takahashi M; Miyakita Y; Narita Y; Ichimura K; Yoshida A
Mod Pathol; 2021 Apr; 34(4):688-700. PubMed ID: 33077924
[TBL] [Abstract][Full Text] [Related]
8. Mitotic count is prognostic in IDH mutant astrocytoma without homozygous deletion of CDKN2A/B. Results of consensus panel review of EORTC trial 26053 (CATNON) and EORTC trial 22033-26033.
Kros JM; Rushing E; Uwimana AL; Hernández-Laín A; Michotte A; Al-Hussaini M; Bielle F; Mawrin C; Marucci G; Tesileanu CMS; Stupp R; Baumert B; van den Bent M; French PJ; Gorlia T
Neuro Oncol; 2023 Aug; 25(8):1443-1449. PubMed ID: 36571817
[TBL] [Abstract][Full Text] [Related]
9. IDH-mutant diffuse gliomas: tips and tricks in the era of genomic tumor classification.
Ammendola S; Broggi G; Barresi V
Histol Histopathol; 2023 Jul; 38(7):739-753. PubMed ID: 36651583
[TBL] [Abstract][Full Text] [Related]
10. The reliability and interobserver reproducibility of T2/FLAIR mismatch in the diagnosis of IDH-mutant astrocytomas.
Yeniçeri İÖ; Yıldız ME; Özduman K; Danyeli AE; Pamir MN; Dinçer A
Diagn Interv Radiol; 2021 Nov; 27(6):796-801. PubMed ID: 34792037
[TBL] [Abstract][Full Text] [Related]
11. A novel grading system combining histological grade and CDKN2A homozygous and hemizygous deletion to predict prognosis in IDH-mutant astrocytoma.
Xi S; Huang Q; Zeng J
J Neuropathol Exp Neurol; 2024 Jan; 83(2):125-130. PubMed ID: 38175671
[TBL] [Abstract][Full Text] [Related]
12. A novel MRI-based deep learning networks combined with attention mechanism for predicting CDKN2A/B homozygous deletion status in IDH-mutant astrocytoma.
Zhang L; Wang R; Gao J; Tang Y; Xu X; Kan Y; Cao X; Wen Z; Liu Z; Cui S; Li Y
Eur Radiol; 2024 Jan; 34(1):391-399. PubMed ID: 37553486
[TBL] [Abstract][Full Text] [Related]
13. CDKN2A mutations have equivalent prognostic significance to homozygous deletion in IDH-mutant astrocytoma.
Yokoda RT; Cobb WS; Yong RL; Crary JF; Viapiano MS; Walker JM; Umphlett M; Tsankova NM; Richardson TE
J Neuropathol Exp Neurol; 2023 Sep; 82(10):845-852. PubMed ID: 37550258
[TBL] [Abstract][Full Text] [Related]
14. IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations.
Yang RR; Shi ZF; Zhang ZY; Chan AK; Aibaidula A; Wang WW; Kwan JSH; Poon WS; Chen H; Li WC; Chung NY; Punchhi G; Chu WC; Chan IS; Liu XZ; Mao Y; Li KK; Ng HK
Brain Pathol; 2020 May; 30(3):541-553. PubMed ID: 31733156
[TBL] [Abstract][Full Text] [Related]
15. Translational significance of CDKN2A/B homozygous deletion in isocitrate dehydrogenase-mutant astrocytoma.
Fortin Ensign SP; Jenkins RB; Giannini C; Sarkaria JN; Galanis E; Kizilbash SH
Neuro Oncol; 2023 Jan; 25(1):28-36. PubMed ID: 35973817
[TBL] [Abstract][Full Text] [Related]
16. Mismatch repair proteins PMS2 and MLH1 can further refine molecular stratification of IDH-mutant lower grade astrocytomas.
Yang RR; Li KK; Zhang ZY; Chan AK; Wang WW; Chan DT; Li WC; Liu XZ; Li FC; Chen H; Ng HK; Mao Y; Shi ZF
Clin Neurol Neurosurg; 2021 Sep; 208():106882. PubMed ID: 34428613
[TBL] [Abstract][Full Text] [Related]
17. The Diagnostic Value of Conventional MRI and CT Features in the Identification of the IDH1-Mutant and 1p/19q Co-Deletion in WHO Grade II Gliomas.
Zhao K; Sun G; Wang Q; Xue Z; Liu G; Xia Y; Yao A; Zhao Y; You N; Yang C; Xu B
Acad Radiol; 2021 Jul; 28(7):e189-e198. PubMed ID: 32359929
[TBL] [Abstract][Full Text] [Related]
18. Preoperative Discrimination of CDKN2A/B Homozygous Deletion Status in Isocitrate Dehydrogenase-Mutant Astrocytoma: A Deep Learning-Based Radiomics Model Using MRI.
Gao J; Liu Z; Pan H; Cao X; Kan Y; Wen Z; Chen S; Wen M; Zhang L
J Magn Reson Imaging; 2024 May; 59(5):1655-1664. PubMed ID: 37555723
[TBL] [Abstract][Full Text] [Related]
19. Association of partial T2-FLAIR mismatch sign and isocitrate dehydrogenase mutation in WHO grade 4 gliomas: results from the ReSPOND consortium.
Lee MD; Patel SH; Mohan S; Akbari H; Bakas S; Nasrallah MP; Calabrese E; Rudie J; Villanueva-Meyer J; LaMontagne P; Marcus DS; Colen RR; Balana C; Choi YS; Badve C; Barnholtz-Sloan JS; Sloan AE; Booth TC; Palmer JD; Dicker AP; Flanders AE; Shi W; Griffith B; Poisson LM; Chakravarti A; Mahajan A; Chang S; Orringer D; Davatzikos C; Jain R;
Neuroradiology; 2023 Sep; 65(9):1343-1352. PubMed ID: 37468750
[TBL] [Abstract][Full Text] [Related]
20. Reproducible imaging-based prediction of molecular subtype and risk stratification of gliomas across different experience levels using a structured reporting system.
Nam YK; Park JE; Park SY; Lee M; Kim M; Nam SJ; Kim HS
Eur Radiol; 2021 Oct; 31(10):7374-7385. PubMed ID: 34374800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
